Increase in thyroid follicular cell tumors in nelfinavir-treated rats observed in a 2-year carcinogenicity study is consistent with a rat-specific mechanism of thyroid neoplasia

Abstract

The carcinogenic potential of nelfinavir mesylate (nelfinavir) was evaluated in a 2-year oral (gavage) study on Sprague-Dawley rats at dose levels of 0 (control), 0 (vehicle control), 100, 300 and 1000 mg/kg per day. At the end of the treatment, increased incidences of thyroid follicular cell hyperplasia and neoplasms were observed at 300 (males) and 1000 mg/kg per day (both sexes). There were no other treatment-related effects and no tumors at other sites. Results from previous studies indicated a number of effects in the liver and thyroid, as well as metabolic profiles that suggested nelfinavir might cause thyroid hyperplasia/neoplasia secondary to hormone imbalance by altering thyroid hormone disposition. To investigate this hypothesis, the effects of nelfinavir on gene expression in rat hepatocytes and liver slices (in vitro), thyroxine plasma clearance, and thyroid gland function were evaluated. Compared to controls, gene expression analyses demonstrated an increased expression of glucuronyltransferase (UDPGT) and CYP450 3A1 in nelfinavir-treated rat hepatocytes and liver slices. In rats treated with nelfinavir (1000 mg/kg per day) for 4 weeks, liver weights and centrilobular hepatocellular hypertrophy were increased and minimal to mild diffuse thyroid follicular cell hypertrophy and follicular cell hyperplasia were evident in the thyroid gland. Thyroid-stimulating hormone (TSH) levels were significantly increased (three-fold), while tri-iodothyronine (T₃)/tetraiodothyronine (T₄) and reverse T₃(rT₃) levels were unchanged, indicating that a compensated state to maintain homeostasis of T₃/T₄ had been achieved. Plasma ¹²⁵I-thyroxine clearance was increased and the plasma thyroxine AUC₀ 48 was decreased (24%) compared to control. In conclusion, these data indicate that thyroid neoplasms observed in the nelfinavir-treated rats were secondary to thyroid hormone imbalance. Increased thyroxine clearance contributes to the effects of nelfinavir on thyroid gland function and is probably a result of UDPGT induction that leads to elevated TSH levels in the rat and eventual thyroid neoplasia. These results are consistent with a well-recognized rat-specific mechanism for thyroid neoplasms.

Keywords

antiviral carcinogenicity HIV nelfinavir T3 T4 thyroid gland function thyroid hormone thyroxine

References

1 Burns-Naas LA , Webber S , Stump DG , Holson JF , Masarjian L , Zorbas M . Absence of embryo-fetal toxicity in rats or rabbits following repeated oral dosing with nelfinavir . Regul Toxicol Pharmacol 2003; 38: 291-303 .

2 Burns-Naas LA , Stump DG , Webber S , Holson JF , Masarjian L , Furman G et al. Absence of developmental and reproductive toxicity in rats following repeated oral dosing with nelfinavir . Regul Toxicol Pharmacol 2003; 38: 304-316 .

3 Burns-Naas LA , White Jr KL , McCay JA , Ivett JL , Zorbas M . Immunotoxicity evaluation of nelfinavir in rats . Hum Exp Toxicol 2005; 24: 67-78 .

4 Hill RN , Erdreich LS , Paynter OE , Roberts PA , Rosenthal SL , Wilkinson CF . Thyroid follicular cell carcinogenesis . Fundam Appl Toxicol 1989; 12: 692-697 .

5 Capen CC . Mechanistic data and risk assessment of selected toxic endpoints of the thyroid gland . Toxicol Pathol 1997; 25: 39-48 .

6 McClain RM . The significance of hepatic microsomal enzyme induction and altered thyroid function in rats. Implications for thyroid gland neoplasia . Toxicol Pathol 1989; 17: 294-306 .

7 Capen CC . Toxic responses of the endocrine system. Casarett & Doull's toxicology: the basic science of poisons, sixth edition. New York: McGraw-Hill , 2001: 711–759.

8 Institute of Laboratory Animal Resources . The guide for the care and use of laboratory animals, seventh edition. Commission on Life Sciences, National Research Council , 1996.

9 Thomas DG , Breslow N , Gart JJ . Trend and homogeneity analyses of proportions and life table data . Comput Biomed Res 1977; 10: 373-381 .

10.

10 Thakur AK , Berry KJ , Mielke Jr PW . A FORTRAN program for testing trend and homogeneity in proportions . Comput Prog Biomed 1985; 19: 229–229 .

11.

11 Dinse GE , Lagakos SE . Regression analysis of tumor prevalence data . J R Stat Soc Ser C: Appl Stat 1983; 32: 236-248 .

12.

12 Peto R , Pike MC , Day NE , Gray RG , Lee PN , Parish S et al. Guidelines for simple sensitive significance tests for carcinogenic effects in long-term animal experiments. Long-term and short-term screening assays for carcinogens: a critical appraisal. Lyon: International Agency for Cancer Research , 1983: 311–426.

13.

13 Levene H . Robust tests for equality of variances. In Olkin I ed. Contributions to probability and statistics: essays in honor of Harold Hotelling. Palo Alto, CA: Stanford University Press , 1960: 278–292.

14.

14 Winer BJ . Statistical principles in experimental design, second edition. New York, NY: McGraw-Hill , 1970: 149–220.

15.

15 Dunnett CW . New tables for multiple comparisons with a control . Biometrics 1964; 20: 482-491 .

16.

16 Hollander M , Wolfe DA . Chapter 4: the two-sample location problem. Nonparametric statistical methods, second edition. New York: John Wiley & Sons , 1999: 67–82.

17.

17 Thakur AK . A FORTRAN program to perform the nonparametric Terpstra–Jonckheere test . Comput Prog Biomed 1984; 18: 235-240 .

18.

18 Furth J . Pituitary cybernetics and neoplasia. The Harvey Lectures. New York, NY: Academic Press , 1968: 47–71.

19.

19 McClain RM , Posch RC , Bosakowski T , Armstrong JA . Studies on the mode of action for thyroid gland tumor promotion in rats by phenobarbitol . Toxicol Appl Pharmacol 1988; 94: 254-265 .

20.

20 McClain RM . Mechanistic considerations for the relevance of animal data on thyroid neoplasia to human risk assessment . Mutat Res 1995; 333: 131-142 .

21.

21 Dohler KD , Wong CC , von zur Muhlen A . The rat as a model for the study of drug effects on thyroid function: consideration of methodological problems . Pharmacol Therapeut 1979; 5: 305-318 .

22.

22 Haseman JK , Huff J , Boorman GA . Use of historical control data in carcinogenicity studies in rodents . Toxicol Pathol 1984; 12: 126-131 .

23.

23 Sokal JE . Occurrence of thyroid cancer . New Engl J Med 1953; 249: 393-397 .

24.

24 Ron E , Modan B . Cancer by tissue of origin: thyroid. Cancer epidemiology and prevention. Philadelphia: WB Saunders Co. , 1982: 837–854.

25.

25 Capen CC , DeLellis RA , Yarrington JT . Endocrine system. In Haschek WM , Rousseaux CG eds. Handbook of toxicologic pathology. San Diego, CA: Academic Press , 1991.

26.

26 McClain RM . Thyroid gland neoplasia: non-genotoxic mechanisms . Toxicol Letts 1992; 64: 397-408 .

27.

27 McClain RM , Levin AA , Posch Downing J . The effect of phenobarbital on the metabolism and excretion of thyroxine in rats . Toxicol Appl Pharmacol 1989; 99: 216-238 .

28.

28 McClain RM . Mechanistic considerations for the relevance of animal data on thyroid neoplasia to human risk assessment . Mutat Res 1995; 333: 131-142 .

29.

29 Visser TJ , Kaptein E , van Toor HR , van Raaij JA , van den Berg KJ , Joe CT et al. Glucuronidation of thyroid hormone in rat liver: effects of in vivo treatment with microsomal enzyme inducers and in vitro assay conditions . Endocrinology 1993; 133: 2177-2186 .

30.

30 Barter RA , Klaassen CD . Rat liver microsomal UDP-glucuronosyltranferase activity toward thyroxine: characterization, induction, and form specificity . Toxicol Appl Pharmacol 1992; 115: 261-267 .

31.

31 Barter RA , Klaassen CD . Reduction of thyroid hormone levels and alteration of thyroid function by four representative UDP-glucuronosyltransferase inducers in rats . Toxicol Appl Pharmacol 1994; 128: 9-17 .

32.

32 Hood AM , Klaassen CD . Differential effects of microsomal enzyme inducers on in vitro thyroxine (T4) and triiodothyronine (T3) glucuronidation . Toxicol Sci 2000; 55: 78-84 .

33.

33 Klaassen CD , Hood AM . Effects of microsomal enzyme inducers on thyroid follicular cell proliferation and thyroid hormone metabolism . Toxicol Pathol 2001; 29: 34-40 .

34.

34 European Public Assessment Report . Scientific discussion of CRIXIVAN ® (indinavir sulphate). Committee for Medicinal Products for Human Use , 2005.

35.

35 Zucker SD , Qin X , Rouster SD , Yu F , Green RM , Keshaven P et al. Mechanism of indinavir-induced hyperbilirubinemia . Proc Nat Acad Sci 2001; 98(22): 12671–12676 .

36.

36 United States Package Insert (USPI) . VIRACEPT ® (nelfinavir mesylate) tables and oral powder. La Jolla, CA: Agouron Pharmaceuticals , 2004.